<DOC>
	<DOCNO>NCT01031212</DOCNO>
	<brief_summary>This phase I trial study side effect best dose investigational drug call DMXAA ( 5-6-dimethylxanthenone-4-acetic acid ) ASA404 give together carboplatin , paclitaxel cetuximab treat patient refractory solid tumor .</brief_summary>
	<brief_title>ASA404 Combination With Carboplatin/Paclitaxel/Cetuximab Treating Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>Phase I 3+3 dose escalation design patient solid tumor previously treat chemotherapy standard treatment option exist . Carboplatin , paclitaxel cetuximab administer standard dos . The dose ASA404 escalate predefined level . One treatment cycle constitute 3 week . A minimum 3 patient enter treatment level , expand 6 subject dose limit toxicity ( DLT ) observe . If one six patient DLT , additional patient enrol high dose . Once maximum tolerate dose ( MTD ) establish , tolerability dose test total 12 patient . The anticipated sample size 18-24 patient . Carboplatin paclitaxel chosen chemotherapy back bone since commonly use combination multiple tumor . Cetuximab choose EGFR inhibitor combination platinum base therapy cetuximab effective lung head neck cancer . In addition safety activity carboplatin/paclitaxel ASA 404 already demonstrate . A weekly schedule ASA choose 1 ) safety weekly schedule test 2 ) preclinical study confirm enhance activity frequent administration 3 ) provide opportunity evaluate safety pharmacokinetics ASA 404 weekly cetuximab .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histological confirm malignancy advance , incurable solid tumor Progression follow standard therapy , acceptable standard treatment option , eligible standard therapy consist platinumbased doublet Measurable evaluable disease . Measurable disease require enrollment dose expansion cohort MTD ECOG 02 Baseline neuropathy grade ≤ 1 leukocyte &gt; 3,000/mcL absolute neutrophil count &gt; 1,500/mcL platelet &gt; 100,000/mcL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; 1.5 X institutional ULN creatinine within 1.5 x normal institutional limit OR creatinine clearance &gt; 60 mL/min/1.73 m2 Ability give write informed consent willingness comply requirement protocol Women childbearing potential must negative pregnancy test within 14 day begin study drug agree use effective method birth control treatment six month last dose study drug Male patient whose sexual partner woman reproductive potential must surgically sterile agree use double method contraception study six month last dose study drug . One method must condom Patients know brain metastasis `` stable disease '' define growth 6 week period definitive therapy ( surgical RT ) , steroid anticonvulsive therapy Chemotherapy , hormonal therapy biologic therapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior start study therapy recover &lt; grade 2 adverse event due prior agent Prior therapy EGFR inhibitor permit Patients receive palliative radiation therapy &lt; 2 week earlier . Patients must recover toxicity radiation Receiving investigational agent Any severe and/or uncontrolled intercurrent medical condition condition could affect participation study Any follow cardiac abnormality : unstable angina pectoris , include Prinzmetal variant angina , New York Heart Association ( NYHA ) Classification Congestive Heart Failure Grade III great , myocardial infarction stroke ≤ 12 month prior study treatment , long QT syndrome , baseline 12 lead ECG QTc &gt; 450msec per central evaluation , history sustain ventricular tachycardia , history ventricular fibrillation Torsades de Pointes , right bundle branch block leave anterior hemiblock ( bifascicular block ) , bradycardia ( &lt; 50 beat per minute ) Concomitant use drug risk cause Torsades de Pointes PT/PTT &gt; 1.5 x ULN Receiving fulldose anticoagulation ( lowdose warfarin central line allow ) History another primary malignancy le 5 year prior , except nonmelanoma skin cancer cervical cancer insitu Major surgery ≤ 4 week prior ( require general anesthesia respiratory assistance ) ( endoscopic exam diagnostic intent allow ) Minor surgery ≤ 2 week prior ( require general anesthesia respiratory assistance ) Insertion vascular access device allow Not recover surgeryrelated complication Systolic BP &gt; 160mmHg and/or diastolic BP &gt; 90mmHg medication hypertension Hemoptysis associate chest malignancy &lt; 4 week ( &gt; 1 teaspoon ) History hypersensitivity reaction TAXOL drug formulate Cremophor® EL ( polyoxyethylated castor oil ) History severe allergic reaction cisplatin platinumcontaining compound History acute hemorrhagic event require hospital admission blood transfusion Pregnant lactate woman Fertile woman men willing comply birth control instructions Any condition compromise compliance objective procedure protocol , judge principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>adult solid tumor</keyword>
	<keyword>antineoplastic agent</keyword>
</DOC>